Biopharmaceuticals manufacturer MGC Pharmaceuticals (ASX: MXC) has seen significant uptake of its cannabinoid medications with prescriptions across Australia and the United Kingdom doubling to 800 patients through the month of October. The update comes as more medical practitioners prescribe phytocannabinoid-derived medications CannEpil®, which targets drug-resistant epilepsy, and MXP100 which is recommended for neurological disorders, inflammation
Read More
Australian bio-pharmaceutical company Zelda Therapeutics (ASX: ZLD) has continued advancing its observational study which is revealing data around the use of medicinal cannabis for improved behaviour in autistic children. Being conducted at the Children’s Hospital of Philadelphia, the observational study uses parent-reported data to identify doses and formulations of cannabis that improve behaviour, anxiety, sleep,
Read More
Medicinal cannabis company Althea Group Holdings (ASX:AGH) has announced record prescription numbers for their medicinal cannabis products in the month of July which has been consolidated by two major corporate partnerships. Prescriptions of the Group’s medical cannabis products increased by 334 patients in the month, bringing the total to 1,523 for the company which listed
Read More